OMB APPROVAL
OMB Number: 3235-0416
Expires:    April 30, 2010
Estimated average burden
Hours per response.182UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-QSB (Mark One)  S QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007  £ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________ to _____________  Commission file number 000-50212  AIDA PHARMACEUTICALS, INC. (Exact name of small business issuer as specified in its charter)   Nevada81-0592184(State or other jurisdiction of
incorporation or organization)(I.R.S. Employer
Identification No.)   31 Dingjiang Road, Jianggan District, Hangzhou, China310016(Address of principal executive offices)(Zip Code)  Issuers telephone number  86-0571-85802712  __________________________________________________________________ (Former name, former address and former fiscal year, if changed since last report)  Check whether the issues (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.                  Yes S     No £  Indicate by check mark whether the registrant is a shell company (as defined in Rule 13b-2 of the Exchange Act). Yes £    No S  APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS  Check whether the registrant filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.          Yes £     No £  APPLICABLE ONLY TO CORPORATE ISSUES  State the number of shares outstanding of each of the issuers classes of common equity, as of the latest practicable date:  As of November 10, 2007, there were 27,000,000 shares of $0.001 par value common stock issued and outstanding.  Transitional Small Business Disclosure Format (Check one):  Yes £    No S  SEC2334(9-05) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.     FORM 10-QSB AIDA PHARMACEUTICALS, INC. INDEX  PagePART I.Financial Information3Item 1. Financial Statements ( Unaudited)3Condensed Consolidated Balance Sheets as of September 30, 2007 (Unaudited) and December 31, 20064Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the Three and Six Months Ended September 30, 2007 and 2006 (Unaudited)5Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2007 and 2006 (Unaudited)6Notes to Condensed Consolidated Financial Statements as of September 30, 2007 (Unaudited)8Item 2.  Managements Discussion and Analysis of Financial Condition or Plan of Operation24Item 3.  Controls and Procedures38PART II.Other Information38Item 1. Legal Proceedings38Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds38Item 3.  Defaults Upon Senior Securities38Item 4.  Submission of Matters to a Vote of Security Holders.39Item 5.  Other Information39Item 6.  Exhibits and Reports on Form 8-K39Signatures40  (Inapplicable items have been omitted)    2   PART I  FINANCIAL INFORMATION  Item 1. Financial Statements (Unaudited)  In  the  opinion  of management, the accompanying unaudited condensed consolidated financial statements included  in this Form 10-QSB reflect all adjustments (consisting only of normal recurring  accruals)  necessary  for  a  fair  presentation  of  the  results of operations for the periods presented.  The results of operations for the periods presented are not necessarily indicative of the results to be expected for the full year.               3    AIDA PHARMACEUTICAL, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS  ASSETSSeptember 30, 2007
(Unaudited)December 31,
2006CURRENT ASSETSCash and cash equivalents$7,693,300$6,116,816Restricted cash2,416,2331,983,237Accounts receivable, net of allowance for doubtful accounts of $655,663 and $639,208 as of September 30, 2007 and December 31, 2006, respectively8,194,94013,777,571Notes receivable, net of discount of $10,255 and $70,717 as of September 30, 2007 and December 31, 2006, respectively4,117,8822,714,234Inventories4,126,4202,806,945Due from related parties86,78441,462Deferred taxes440,500295,714Other receivables, prepaid expenses, and other assets211,023146,694Marketable securities-362,758Due from employees1,544,097264,182Prepayments for goods122,917118,327Total current assets28,954,09628,627,940Plant and equipment, net15,353,79413,977,611Land use rights, net3,836,2633,747,225Construction in progress241,47728,430Patents, net5,540,7795,724,000Long-term investments199,713295,749Deposits4,089,464953,267Deferred taxes421,628456,222Total long-term assets29,683,11825,182,504TOTAL ASSETS$58,637,214$53,810,444LIABILITIES AND SHAREHOLDERS EQUITYCURRENT LIABILITIESAccounts payable$2,446,547$3,332,174Other payables and accrued liabilities2,609,1852,150,079Advance for research and development340,026251,050Short-term debt29,405,23423,915,452Current portion of long-term debt1,331,4163,717,380Due to related parties27,06327,063Taxes payable62,278352,998Customer deposits1,063,060335,391Due to employees412,420122,440Deferred taxes105,004172,844Total current liabilities37,802,23334,376,871LONG-TERM LIABILITIESNotes payable1,920,9341,920,934Advance for research and development871,4041,065,478Deferred taxes1,014,008917,530Minority interests5,956,9985,177,413Total long-term liabilities9,763,3449,081,355TOTAL LIABILITIES47,565,57743,458,226COMMITMENTS AND CONTINGENCIESSHAREHOLDERS EQUITYCommon stock, $0.001 par value; 75,000,000 shares authorized; 27,000,000 shares
issued and outstanding at September 30, 2007 and December 31, 2006, respectively27,00027,000Additional paid-in capital5,204,3525,204,352Retained earnings (the restricted portion is $998,149 at September 30, 2007 and
December 31, 2006, respectively)4,923,4674,590,079Accumulated other comprehensive income916,818530,787Total shareholders equity11,071,63710,352,218TOTAL LIABILITIES AND SHAREHOLDERS EQUITY$58,637,214$53,810,444   See accompanying notes to condensed consolidated financial statements.  4


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED)  FOR THE THREE
MONTHS ENDED
SEPTEMBER  30,FOR THE NINE
MONTHS ENDED
SEPTEMBER 30,2007200620072006REVENUES, (NET)$7,373,770$7,023,891$18,687,283$19,659,235COST OF GOODS SOLD(3,557,685)(3,103,516)(9,740,952)(9,679,567)GROSS PROFIT3,816,0853,920,3758,946,3319,979,668Selling and distribution1,387,8181,175,0003,515,7764,728,989General and administrative991,2161,306,2263,006,7992,896,205Research and development74,51445,323238,15945,111INCOME FROM OPERATIONS1,362,5371,393,8262,185,5972,309,363OTHER INCOME (EXPENSES)Interest expense, net(465,282)(459,511)(1,180,813)(1,114,105)Government grants46,131551,42095,9981,097,724(Loss) gain on sales of investment(10,457)-(10,457)12,490Gain on sale of marketable securities--120,356-Other income (loss), net(3,478)(77,358)(122,876)(120,734)INCOME BEFORE INCOME TAXES929,4511,408,3771,087,8052,184,738INCOME TAXES(153,182)(217,720)(191,349)(445,047)INCOME BEFORE MINORITY INTERESTS776,2691,190,657896,4561,739,691MINORITY INTERESTS(257,208)(271,372)(563,068)(413,018)NET INCOME519,061919,285333,3881,326,673OTHER COMPREHENSIVE INCOMEForeign currency translation gain30,09873,643492,663160,785OTHER COMPREHENSIVE INCOME
BEFORE INCOME TAXES30,09873,643492,663160,785INCOME TAXES RELATED TO OTHER COMPREHENSIVE INCOME(7,946)(24,302)(130,063)(54,012)OTHER COMPREHENSIVE INCOME ,
NET OF INCOME TAXES22,15249,341362,600106,773COMPREHENSIVE INCOME$541,213$968,626$695,988$1,433,446WEIGHTED AVERAGE SHARES OUTSTANDING
BASIC AND DILUTED27,000,00025,000,00027,000,00025,000,000NET INCOME PER COMMON SHARE,
BASIC AND DILUTED$0.02$0.04$0.01$0.05    See accompanying notes to condensed consolidated financial statements.


5


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) For the Nine Months Ended September  30,20072006CASH FLOWS FROM OPERATING ACTIVITIES:Net  income$333,388$1,326,673Adjustments to reconcile net  income to net cash provided by operating activities:Depreciation and amortization1,476,3391,281,280Provision for doubtful accounts16,455-Amortization of discount on notes receivable(64,228)-Loss of disposal of fixed assets28,146230Amortization of deferred compensation-356,878Deferred taxes(81,554)142,717Gain on sale of marketable securities(120,356)-Gain on disposal of discontinued operation-(12,490)Minority interests share of net income563,068413,018Changes in operating assets and liabilities, net of effects of acquisition:(Increase) Decrease In:Accounts receivable5,566,175(3,471,378)Inventories(1,319,475)(435,080)Other receivables, prepaid expenses, and other assets(64,328)97,309Prepayments for goods(4,590)(146,414)Increase (Decrease) In:Accounts payable(885,626)2,145,059Other payables and accrued liabilities441,287(273,451)Advance for research and development(105,099)-Due to employees289,981(365,431)Taxes payable(290,719)129,085Customer deposits727,669(608,739)Net cash provided by operating activities6,506,533579,266CASH FLOWS FROM INVESTING ACTIVITIES:Restricted cash(432,996)(416,959)Purchases of plant and equipment(1,924,724)(1,178,141)Purchases of construction in progress(206,699)(43,612)Cash received from sale of plant and equipment-820Purchase of land use right-(442,573)Deposit for land use right-(1,005,737)Deposit for long term investment(2,578,149)-Deposit for plant and equipment(751,871)-Deposit for patent-(125,069)Repayment of notes receivable973,320-Issuance of notes receivable(2,312,740)(860,728)Due from related parties-(14,163)Due from employees(1,279,916)797,710Proceeds from sale of marketable securities376,481-Proceeds from disposal of patent101,188-Proceeds from disposal of investment96,035137,559Purchase of investment-(79,933)Purchase of subsidiaries, net of cash acquired-(1,977,393)Net cash used in investing activities(7,940,071)(5,208,219)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from short-term debt23,290,4203,877,511Proceeds from capital contribution-187,500Repayments of short-term debt(20,186,602)-Proceeds from long-term debt-75,911Proceeds from notes payable-2,149,532Repayment of advances to related parties(45,322)(20,072)Net cash provided by financing activities3,058,4966,270,382INCREASE IN CASH AND CASH EQUIVALENTS1,624,9581,641,429Effect of exchange rate changes on cash(48,474)163,674Cash and cash equivalents at beginning of period6,116,8163,129,450CASH AND CASH EQUIVALENTS AT END OF PERIOD$7,693,300$4,934,553  See accompanying notes to condensed consolidated financial statements.


6


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)  For the Nine Months Ended September  30,20072006SUPPLEMENTARY CASH FLOW INFORMATIONIncome taxes paid$610,430$172,644Interest paid$1,050,689$1,139,094  SUPPLEMENTAL NON-CASH INVESTING DISCLOSURES:  1. During the nine months ended September 30, 2007 and 2006, $46,600 and $274,229 was transferred from deposits to patents.2. During the nine months ended September 30, 2007 and 2006, $33,790 and $781,948 was transferred from construction in progress to
plant and equipment.3.During the nine months ended September 30, 2007 and 2006, $97,783 and $268,596 was transferred from deposits to plant
and equipment.


7


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   1. ORGANIZATION AND PRINCIPAL ACTIVITIES  The primary operations of Aida Pharmaceuticals, Inc. and subsidiaries (the Company) are the development, production and distribution of cardiovascular and anti cancer drugs, in the form of powder for injection, liquid for intravenous injection, capsule, tablet, ointment, etc., within the Peoples Republic of China (PRC).  2. BASIS OF PRENTATION  The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the requirements for reporting on Form 10-QSB and Item 310(b) of Regulation S-B. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the consolidated financial position and the consolidated results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full year. The condensed consolidated balance sheet information as of December 31, 2006 was derived from the audited consolidated financial statements included in the Companys Annual Report Form 10-KSB.  These interim financial statements should be read in conjunction with that report.  3. PRINCIPLES OF CONSOLIDATION  The unaudited condensed consolidated financial statements include the accounts of Aida Pharmaceuticals, Inc. (Formerly BAS Consulting, Inc.) and the following subsidiaries:  (i) Earjoy Group Limited (Earjoy) (100% subsidiary of Aida); (ii) Hangzhou Aida Pharmaceutical Co., Ltd. (HAPC) (100% Subsidiary of Earjoy); (iii) Hangzhou Boda Medical Research and Development Co., (Boda) (100% Subsidiary of HAPC); (iv) Hainan Aike Pharmaceutical Co., Ltd. (Hainan) (60.61%% subsidiary of HAPC) and Yang Pu Aike Pharmaceutical Co., Ltd. (Yangpu) (95% subsidiary of Hainan). HAPC exercises significant influence over Hainan by controlling over 50% of the voting rights; (v) Changzhou Fangyuan Pharmaceutical Co., Ltd. (Fangyuan) (66% subsidiary of HAPC). (vi) Shanghai Qiaer Bio-Technology Co., Ltd. (Qiaer) (77.5% subsidiary of HAPC)  All significant inter-company accounts and transactions have been eliminated in consolidation.


8


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   4. CONCENTRATIONS  The Company has major customers who accounted for the following percentages of total sales and total accounts receivable in 2007 and 2006:  SalesAccounts ReceivableMajor CustomersFor the Nine Months Ended September 30, 2007For the Nine Months Ended September 30, 2006September 30,
2007December 31,
2006Company A-24%-30%Company B-7%-2%Company C-4%-2%Company D-3%-30%Company E32%-30%-Company F6%-5%-Company G5%-5%-  The Company has major suppliers who accounted for the following percentages of total purchases and total accounts payable in 2007 and 2006:  PurchasesAccounts PayableMajor SuppliersFor the Nine Months Ended September 30, 2007For the Nine Months Ended September 30, 2006September 30,
2007December 31,
2006Company H19%9%16%7%Company I14%6%13%3%  The sole market of the Company is the PRC for the periods ended September 30, 2007 and 2006.  Of the total revenue for the nine months ended September 30, 2007 and 2006, 69% and 66% was fully dependent on the patent for Etimicin Sulfate owned by the Company.  5. USE OF ESTIMATES  The preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.  Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ materially from those estimates.


9


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   6. FOREIGN CURRENCY TRANSLATION  The accompanying condensed consolidated financial statements are presented in United States dollars.  The functional currency of the Company is the Renminbi (RMB). The condensed consolidated financial statements are translated into United States dollars from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred.  September 30,
2007December 31,
2006September 30,
2006Period end RMB:         US$ exchange rate7.51087.80877.9087Average period RMB:  US$ exchange rate7.65987.93957.9895  7. FAIR VALUE OF FINANCIAL INSTRUMENTS  The Companys financial instruments include cash and cash equivalents, restricted cash, accounts receivable, notes receivable, due to/from related parties, other receivables and prepaid expenses, due to employees, prepayments for goods, accounts payable, other payable and accrued liabilities, accrued expenses, short-term debt, taxes payable and customer deposits.  Management has estimated that the carrying amount approximates fair value due to their short-term nature. The fair value of the Companys long-term notes payable are estimated based on the current rates offered to the Company for debt of similar terms and maturities. Under this method, the Companys fair value of long-term notes payable was not significantly different from the carrying value at September 30, 2007.  8. EARNINGS  PER SHARE  Basic earning per share is computed by dividing net income by the weighted-average number of common shares outstanding during the periods. Diluted earning per share is computed similar to basic earning  per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive securities outstanding for the periods presented.  9. ADOPTION OF NEW ACCOUNTING POLICY  Effective January 1, 2007, the Company adopted Financial Accounting Standards Board (FASB) Interpretation No. 48, Accounting for Uncertainty in Income Taxes ("FIN 48"), an interpretation of FASB statement No. 109, Accounting for Income Taxes. The interpretation addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under FIN 48, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. FIN 48 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of September 30, 2007, the Company does not have a liability for unrecognized tax benefits.


10


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   9. ADOPTION OF NEW ACCOUNTING POLICY (CONTINUED)  The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company is subject to U.S. federal or state income tax examinations by tax authorities for years after 2005. During the periods open to examination, the Company has net operating loss and tax credit carry forwards for U.S. federal and state tax purposes that have attributes from closed periods. Since these NOLs and tax credit carry forwards may be utilized in future periods, they remain subject to examination. The Company also files certain tax returns in China. As of September 30, 2007 the Company was not aware of any pending income tax examinations by China tax authorities.  The Company's policy is to record interest and penalties on uncertain tax provisions as income tax expense. As of September 30, 2007, the Company has no accrued interest or penalties related to uncertain tax positions.  10. NEW ACCOUNTING PRONOUNCEMENTS  In September 2006, the FASB issued Statement of Financial Accounting Standards (SFAS) No. 157, "Fair Value Measurements," which provides enhanced guidance for using fair value to measure assets and liabilities. SFAS No. 157 provides a common definition of fair value and establishes a framework to make the measurement of fair value in generally accepted accounting principles more consistent and comparable. SFAS No. 157 also requires expanded disclosures to provide information about the extent to which fair value is used to measure assets and liabilities, the methods and assumptions used to measure fair value, and the effect of fair value measures on earnings. SFAS No. 157 is effective for financial statements issued in fiscal years beginning after November 15, 2007 and to interim periods within those fiscal years. The Company is currently in the process of evaluating the effect, if any, the adoption of SFAS No. 157 will have on its consolidated results of operations, financial position, or cash flows.  In February 2007, the FASB issued FASB Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities −− Including an amendment of FASB Statement No. 115 (“FAS 159”).  FAS 159, which becomes effective for the Company on January 1, 2008. This standard permits companies to choose to measure many financial instruments and certain other items at fair value and report unrealized gains and losses in earnings. Such accounting is optional and is generally to be applied instrument by instrument. The Company does not anticipate that election, if any, of this fair value option will have a material effect on the results or operations or consolidated financial position.


11


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)  11. NOTES RECEIVALBE  Notes receivable consist of the following:  Notes receivable from unrelated companies:September 30,December 31,20072006(Unaudited)Due January 30, 2007  (subsequently settled)$-$256,125Due January 31, 2007  (subsequently settled)-502,366Due January 31, 2007  (subsequently settled)-14,189Due August 31, 2007 (subsequently settled)-12,806Due September 20, 2007 (subsequently settled)-487,242Due October 31, 2007 (subsequently settled)599,137576,280Due November 11, 2007 (subsequently settled)399,425384,187Due November 30, 2007133,142128,062Due December 1, 200724,22323,299Due December 1, 20077,3817,100Due December 1, 2007399,42564,032Due December 14, 2007340,648329,263Due December 1, 20077,988-Due December 15, 2007, interest at 5.58% per annum1,893,847-Due December 15, 2007, interest at 6% per annum66,571-Due December 20, 2007123,208-Due December 31, 2007133,142-Subtotal4,128,1372,784,951Less: Discount10,25570,717Total notes receivable, net$4,117,882$2,714,234   Notes receivable are unsecured.  In 2007, an interest-free note was provided to a company for its assistance in research and development activities. The Company recorded research and development expense and a discount on the notes receivable of $3,766 based on the present value of the notes receivable using a 6% discount rate.  For the nine months ended September 30, 2007 and 2006, $64,228 and $0 of interest income was recognized in the accompanying condensed consolidated statements of income from the amortization of the discount.  12. INVENTORIES  Inventories consist of the following:  September 30,December 31,20072006(Unaudited)Raw materials$1,223,273$1,712,850Work-in-progress1,127,615500,997Finished goods1,775,532593,098Total$4,126,420$2,806,945


12


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   13. PLANT AND EQUIPMENT  Plant and equipment consist of the following:  September 30,December 31,20072006(Unaudited)At cost:Buildings$9,422,313$8,944,313Machinery10,747,2119,206,036Motor vehicles752,710742,689Office equipment1,334,677668,428Leasehold improvements463,604455,35622,720,51520,016,822Less:  Accumulated depreciationBuildings1,580,855880,647Machinery4,381,6833,504,714Motor vehicles465,240445,523Office equipment577,085412,530Leasehold improvements361,858795,7977,366,7216,039,211Plant and equipment, net$15,353,794$13,977,611  The net book value of buildings and machinery pledged for certain bank loans at September 30, 2007 and December 31, 2006 is $4,969,991 and $4,892,624, respectively.  Also see Note 17.  Depreciation expense for the nine months ended September 30, 2007 and 2006 is $1,147,349 and $1,002,776, respectively.  14. LAND USE RIGHTS  September 30,December 31,20072006(Unaudited)Cost$4,101,870$3,945,385Less: Accumulated amortization265,607198,160Land use rights, net$3,836,263$3,747,225  Amortization expense for nine months ended September 30, 2007 and 2006 is $58,429 and $35,019 respectively.  Amortization expense for the remaining part of 2007, for the next four years and thereafter is as follows:  2007$19,861200879,450200979,450201079,450201179,450Thereafter3,498,602Total$3,836,263


13


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)  14. LAND USE RIGHTS (CONTINUED)  The net book value of the land use right pledged for certain bank loans at September 30, 2007 and December 31, 2006 is $1,176,268 and $1,572,139, respectively.  Also see Note 17.  15. PATENTS  September 30,December 31,20072006(Unaudited)Cost$6,379,864$6,446,568Less: Accumulated amortization839,085722,568Patents, net$5,540,779$5,724,000  Amortization expense for nine months ended September 30, 2007 and 2006 is $270,561 and $243,484 respectively.  Amortization expense for the remaining part of 2007, for the next four years and thereafter is as follows:  2007$85,4792008316,9502009305,0682010303,3192011302,077Thereafter4,227,886Total$5,540,779  16. DEPOSITS  Deposits consist of the following:  September 30, 2007December 31,
2006(Unaudited)Patent$583,826$703,702Plant and equipment769,68897,783Long-term investment2,735,950151,782Total$4,089,464$953,267  During the nine months ended September 30, 2007, the Company paid $769,688 as deposits to acquire certain equipment.  Deposits of $97,783 were transferred to plant and equipment during the nine months ended September 30, 2007.  During the nine months ended September 30, 2007, a deposit of $46,600 was transferred to a patent.  During the nine months ended September 30, 2007, the Company paid $66,571 as a refundable deposit to acquire 10% of outstanding shares of Beijing Beimei Union Real Estate Development Co., Ltd.   During the nine months ended September 30, 2007, the Company paid $2,517,597, as a refundable deposit to acquire 60% of the outstanding shares of Jiangsu Microbial Research Institute.


14   AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)    17. SHORT TERM DEBT  Short-term debt consists of the following: September 30, 2007December 31,
2006Bank Loans:(Unaudited)Loans from Industrial and Commercial Bank of China Qingchun Branch, due August 20, 2007, monthly interest only payments at 6.732% per annum, secured by assets owned by the Company (subsequently repaid on its due date).$-$640,311Loans from Industrial and Commercial Bank of China Qingchun Branch, due August 15, 2007, monthly interest only payments at 6.732% per annum, secured by assets owned by the Company (subsequently repaid on its due date).-800,389Loans from Industrial and Commercial Bank of China Qingchun Branch, due July 26, 2007, monthly interest only payments at 6.435% per annum, secured by assets owned by the Company (subsequently repaid on its due date).-896,436Loans from Industrial and Commercial Bank of China Qingchun Branch, due June 6, 2007, monthly interest only payments at 6.435% per annum, secured by assets owned by the Company (subsequently repaid on its due date).-1,280,623Loans from Industrial and Commercial Bank of China Qingchun Branch, due June 27, 2007, monthly interest only payments at 6.435% per annum, secured by assets owned by the Company (subsequently repaid on its due date).-768,374Loans from Industrial and Commercial Bank of China Qingchun Branch, due August 15, 2008, monthly interest only payments at 7.524% per annum, secured by assets owned by the Company. Also see Note 13.665,708-Loans from Industrial and Commercial Bank of China Qingchun Branch, due July 18, 2008, monthly interest only payments at 7.524% per annum, secured by assets owned by the Company. Also see Note 13.931,991-Loans from Industrial and Commercial Bank of China Qingchun Branch, due August 8, 2008, monthly interest only payments at 7.524% per annum, secured by assets owned by the Company. Also see Note 13.832,135-Loans from Industrial and Commercial Bank of China Qingchun Branch, due June 6, 2008, monthly interest only payments at 7.227% per annum, secured by assets owned by the Company. Also see Note 13.1,331,416-Loans from Industrial and Commercial Bank of China Qingchun Branch, due June 18, 2008, monthly interest only payments at 7.227% per annum, secured by assets owned by the Company. Also see Note 13.798,850-Loan from Bank of Communication Qingchun Branch, due June 5, 2007 monthly interest only payments at 6.435% per annum, guaranteed by Nanwang Information Industry Group Co., Ltd (subsequently repaid on its due date).-1,290,623


15


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   17. SHORT TERM DEBT (CONTINUED)  September 30, 2007December 31,
2006(Unaudited)Loan from Bank of Communication Qingchun Branch, due June 19, 2007 monthly interest only payments at 6.435% per annum, guaranteed by Nanwang Information Industry Group Co., Ltd (subsequently repaid on its due date).-1,290,623Loan from Hangzhou Commercial Bank Gaoxin Branch due February 27, 2007, monthly interest only payments at 5.3625% per annum, guaranteed by Xinchang Guobang Chemicals Co., Ltd (subsequently repaid on its due date).-1,290,623Loan from Hangzhou Commercial Bank Gaoxin Branch due February 1, 2008, monthly interest only payments at 5.6100% per annum, guaranteed by Xinchang Guobang Chemicals Co., Ltd.1,331,416-Loan from Bank of China Kaiyuan Branch due May 8, 2007, monthly interest only payments at 6.7275% per annum, guaranteed by Xinchang Guobang Chemicals Co., Ltd (subsequently repaid on its due date).-1,034,498Loan from Bank of China Kaiyuan Branch due May 16, 2007, monthly interest only payments at 6.7275% per annum, guaranteed by Xinchang Guobang Chemicals Co., Ltd (subsequently repaid on its due date).-650,311Loan from Bank of China Kaiyuan Branch due April 17, 2007, monthly interest only payments at 6.417% per annum, guaranteed by Xinchang Guobang Chemicals Co., Ltd (subsequently repaid on its due date).-2,187,059Loan from Huaxia Bank Wenhui Branch due April 3, 2007, monthly interest only payments at 6.417% per annum, guaranteed by Ningbo Tianheng Co., Ltd (subsequently repaid on its due date).-778,374Loans from Industrial and Commercial Bank of China Qingtai Branch, due August 4, 2007, monthly interest only payments at 6.138% per annum, guaranteed by Hangzhou Jinou Group (subsequently repaid on its due date).-1,290,623Loan from Bank of Communication Qingchun Branch, due March 29, 2008 monthly interest only payments at 6.7095% per annum, guaranteed by Nanwang Information Industry Group Co., Ltd.3,328,540-Loan from Bank of Communication Qingchun Branch, due June 5, 2008 monthly interest only payments at 6.8985% per annum, guaranteed by Nanwang Information Industry Group Co., Ltd.1,331,416-Loan from Bank of Communication Qingchun Branch, due June 18, 2008 monthly interest only payments at 6.8985% per annum, guaranteed by Nanwang Information Industry Group Co., Ltd.1,331,416-


16


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   17. SHORT TERM DEBT (CONTINUED)  September 30, 2007December 31,
2006(Unaudited)Loan from Bank of China Kaiyuan Branch due April 27, 2008, monthly interest only payments at 7.3485% per annum, guaranteed by Xinchang Guobang Chemicals Co., Ltd.1,331,416-Loan from Bank of China Kaiyuan Branch due May 16, 2008, monthly interest only payments at 7.3485% per annum, guaranteed by Xinchang Guobang Chemicals Co., Ltd.665,708-Loan from Bank of China Kaiyuan Branch due May 9, 2008, monthly interest only payments at 7.3485% per annum, guaranteed by Xinchang Guobang Chemicals Co., Ltd.1,997,124-Loan from Evergrowing Bank Hangzhou Branch due June 4, 2008, monthly interest only payments at 7.3485% per annum, guaranteed by Xinchang Guobang Chemicals Co., Ltd.1,997,124-Loan from China Development Bank Haikou Branch, due December 21, 2007 and monthly interest only payments at 6.138% per annum, guaranteed by Haikou Assure Investment Ltd.239,655394,187Loans from Changzhou Commercial Bank, due June 20, 2007, monthly interest only payments at 8.37% per annum, secured by assets owned by the Company (subsequently repaid on its due date).-1,822,081Loans from Changzhou Commercial Bank, due June 20, 2007, monthly interest only payments at 8.37% per annum, secured by assets owned by the Company (subsequently repaid on its due date).-1,143,351Loans from Changzhou Commercial Bank, due May 18, 2007, monthly interest only payments at 8.37% per annum, guaranteed by Jiangyin Huilun Co. Ltd (subsequently repaid on its due date).-270,614Loans from Changzhou Commercial Bank, due May 28, 2008, monthly interest only payments at 8.541% per annum, secured by assets owned by the Company. Also see Note 14.1,883,954-Loans from Changzhou Commercial Bank, due May 28, 2008, monthly interest only payments at 8.541% per annum, secured by assets owned by the Company. Also see Note 14.1,178,304-Loans from Changzhou Commercial Bank, due November 28, 2008, monthly interest only payments at 8.541% per annum, guaranteed by Jiangyin Huilun Weave Co., Ltd.1,331,416-Total short-term bank loans$22,507,589$17,829,100


17


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   17. SHORT TERM DEBT (CONTINUED)  Notes payable:Due May 30, 2007 (subsequently repaid on its due date)$-$190,365Due May 8, 2007 (subsequently repaid on its due date)-1,024,498Due June 21, 2007 (subsequently repaid on its due date)-1,280,623Due August 31, 2007 (subsequently repaid on its due date)-768,374Due December 30, 2007, interest at 9.00% per annum665,708640,311Due January 15, 2007 (subsequently repaid on its due date)-133,185Due April 5, 2007, interest at 5.58% per annum (subsequently repaid on its     due date)-320,156Due April 20, 2007, interest at 5.58% per annum (subsequently repaid on its due date)-320,156Due November 6, 2007 (subsequently repaid on its due date)122,336-Due November 30, 2007, interest at 5.85% per annum532,566512,249Due December 31, 2007, guaranteed by Donghong Taisheng Co., Ltd266,283256,125Due October 15, 2007, interest at 6.40% per annum, guaranteed by Ge Xiaohu (subsequently repaid on its due date)665,708640,310Due December 12, 20071,331,416-Due December 19, 2007196,916-Due February 23, 2008665,708-Due April 20, 2008, interest at 5.58% per annum332,854-Due March 14, 200899,857-Due May 1, 2008, interest at 6.00% per annum886,590-Due September 30, 2008798,850-Due October 30, 2008, interest at 5.85% per annum332,853-Total notes payable6,897,6456,086,352Total short-term debt$29,405,234$23,915,452  All the notes payable are subject to bank charges of 0.05% of the principal as a commission on each loan transaction. Bank charges for notes payable were $7,850 and $1,908 for nine months ended September 30, 2007 and 2006, respectively.  Restricted cash of $2,416,233 is held as collateral for the following notes payable at September, 30, 2007:  Due November 6, 2007$122,336Due December 12, 20071,331,416Due December 19, 2007196,916Due March 14, 200899,857Due February 23, 2008665,708Total$2,416,233


18


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   18. LONG TERM DEBT  Long-term debt consists of the following:  September 30, 2007December31, 2006(Unaudited)Loans from Communication Bank of China Changzhou Branch, due September 9, 2007, monthly interest only payments at 5.58% per annum, guaranteed by Changzhou High-Tech Development District Co., Ltd.$-$3,717,380Loans from Communication Bank of China Changzhou Branch, due September 9, 2008, monthly interest only payments at 5.58% per annum, guaranteed by Changzhou High-Tech Development District Co., Ltd.1,331,416-Total long-term bank loan1,331,4163,717,380Less: current portion(1,331,416)(3,717,380)Long-term portion$-$-  Notes payable to unrelated companies:Due December 31, 2008, interest charged at 1% per annum and guaranteed by Donghong Taisheng Co., Ltd$256,124$256,124Due December 31, 2009, interest charged at 1% per annum and guaranteed by Donghong Taisheng Co., Ltd384,187384,187Due February 20, 2009, interest charged at 1% per annum and unsecured1,280,6231,280,623Total notes payable$1,920,934$1,920,934Total long-term debt$1,920,934$1,920,934  19. LONG-TERM INVESTMENTS  Long-term investments consist of the following:  Ownership
InterestSeptember 30, 2007Ownership
InterestDecember 31, 2006(Unaudited)At cost:Hangzhou Longde Medical Machinery Co., Ltd.-$-10.6%$103,656Hangzhou Jin'ou Medicine Co., Ltd15%199,17315%192,093$199,713$295,749  On July 28, 2007, the Company entered into agreement with Hangzhou Handcrafts Cooperate Association to transfer its 10.6% interest in Hangzhou Longde Medical Machinery Co., Ltd. for $93,199 resulting in a loss of $10,457.


19


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   20. INCOME TAXES  a) Effect of Changes in Chinese Corporate Tax Law  On March 16, 2007, the National Peoples Congress of China approved the Corporate Income Tax Law of the Peoples Republic of China (the new CIT Law), which is effective from January 1, 2008. Under the new CIT Law, the corporate income tax rate applicable to the Company starting from January 1, 2008 will be 25%, replacing the currently applicable tax rate of 33%. The new CIT Law has an impact on the deferred tax assets and liabilities of the Company. As there is still no detailed implementation rulings released, the Company adjusted deferred tax balances as of September 30, 2007 based on their best estimates and will continue to assess the impact of such new law in the future. Effects arising from the enforcement of new CIT law have been reflected in the accompanying condensed consolidated financial statements.  In 2006, HAPC applied to the local tax authority for a favorable corporate income tax rate of 26.4% for companies registered in coastal economic zone of PRC, which was approved in October 2006. As a result, the corporate income tax rate applicable to HAPC was changed to 26.4% from 33%.  Hainan and Yangpu are subsidiaries registered in Hainan, PRC, and their corporate income tax rate of 15% is the tax rate for companies registered in Hainan, PRC in accordance with the relevant tax laws in PRC.   Fangyuan is a subsidiary of HAPC and its applicable corporate income tax rate is 15%, since the company was recognized as high-tech companies by the PRC government.  However, in accordance with the relevant taxation laws in the PRC, from the time that a company has its first profitable tax year, a foreign investment company is exempt from corporate income tax for its first two years and is then entitled to a 50% tax reduction for the succeeding three years. For Hangzhou and Hainan, the first profitable year for income tax purposes as a foreign investment company was 2004.  Income tax expense for the nine months ended September 30, 2007 and 2006 is summarized as follows:  For the Nine Months Ended September 30,(Unaudited)20072006Current:Provision for State Corporation Income Tax$248,094$274,845Provision for Local Corporation Income Tax24,80927,485272,903302,330Deferred:Provision for State Corporation Income Tax(74,140)129,743Provision for Local Corporation Income Tax(7,414)12,974(81,554)142,717Income tax$191,349$445,047  The Companys income tax expense differs from the expected tax expense for the nine months ended September 30, 2007 and 2006 (computed by applying the CIT rate of 26.4 percent to income before income taxes) as follows:


20


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)    20. INCOME TAXES (CONTINUED)  For the Nine Months Ended September 30, (Unaudited)20072006Computed expected expense$287,181$764,658Tax rate adjustment(4,391)-Valuation allowance21,435(12,167)Time difference(81,554)99,022Tax exemptions(31,322)(406,466)Income tax expense$191,349$445,047  The tax effects of temporary differences that give rise to the Companys net deferred tax assets and liabilities as of September 30, 2007 and December 31, 2006 are as follows:  September 30,
2007December 31,
2006(Unaudited)Deferred tax assets:Current portion:Consulting and audit expenses$105,564$105,564Selling and distribution expenses224,322102,404Bad debt provision66,32941,949Other44,28545,797Subtotal440,500295,714Non-current portion:Depreciation82,80065,416Impairment and amortization12,46241,502Bad debt provision24,29924,299Pre-operating expenses12,54612,546Research and development costs281,453281,453Other40,80442,307Less: Valuation allowance(32,736)(11,301)Subtotal421,628456,222Total deferred tax assets862,128751,936Deferred tax liabilities:Current portion:Sales cut-off27,170134,954Unrealized gains from marketable securities30,71030,710Other47,1247,180Subtotal105,004172,844


21


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   20. INCOME TAXES (CONTINUED)  Non-current portion:Subsidy income192,105192,105Depreciation59,52028,963Research and development costs35,31535,315Government grant58,84158,841Other75,74635,274Intangible assets of acquisition592,481567,032Subtotal1,014,008917,530Total deferred tax liabilities1,119,0121,090,374Net deferred tax liabilities$(256,884)$(338,438)  (b) Value Added Tax (VAT)  Enterprises or individuals who sell commodities, engage in repair and maintenance or import or export goods in the PRC are subject to a value added tax in accordance with Chinese Laws.  The value added tax standard rate is 17% of the gross sale price. A credit is available whereby VAT paid on the purchases of semi-finished products or raw materials used in the production of the Companys finished products can be used to offset the VAT due on the sales of the finished products.  The VAT payable of $230,636 and $301,103 at and September 30, 2007 and December 31, 2006, respectively, are included in other payables and accrued expenses in the accompanying condensed consolidated balance sheets.  21. MARKETABLE SECURITIES  The Company purchased an investment fund at a cost of $256,125 on September 6, 2006. The fair market value of the fund as of December 31, 2006 was $362,758. The difference between the market value and the cost of $106,633 was recognized as other comprehensive income at December 31, 2006, and was included as a separate component of shareholders equity for year then ended.  The securities were classified as available-for-sale.  On January 28, 2007, the Company sold the marketable securities for $376,481 resulting in a gain of $120,356 which was included in the condensed consolidated statement of income and comprehensive income for the nine months ended September 30, 2007.  22. COMMITMENTS AND CONTINGENCIES  (a) Lease Commitments  The Company occupies plant and office space leased from third parties. Accordingly, for the nine months ended September 30, 2007 and 2006, the Company recognized rental expense for these spaces of $312,696 and $138,603 respectively.  As of September 30, 2007, the Company has outstanding commitments with respect to non-cancelable operating leases for real estate, which fall due as follows:


22


AIDA PHARMACEUTICALS, INC. (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006 (UNAUDITED)   22. COMMITMENTS AND CONTINGENCIES (CONTINUED)  Period Ending September 30,Amount2007$63,0552008153,4152009144,6832010144,6832011128,706Thereafter67,312Total$701,854  (b) Capital Commitment  As of September 30, 2007, the Company has outstanding commitments with respect to non-cancelable contract, which fall due as follows:  Period Ending September 30Amount2007$420,585  (c) Contingencies  In 2006, the Company brought a legal action against Jiangxi Pharmaceutical Co., Ltd. and Hainan Licheng Pharmaceuticals Co., Ltd. for their infringement upon the patent of Etimicin transfusion. As the plaintiff, the Company has claimed compensation of approximately $38,590 for the infringement. According to the judges report from the local court in Haikou, PRC, on December 30, 2006, the Company won the lawsuit and Jiangxi Pharmaceutical Co., Ltd. and Hainan Licheng Pharmaceuticals Co., Ltd. will be required to pay $38,590 as compensation to the Company. However, Jiangxi Pharmaceutical Co., Ltd. and Hainan Licheng Pharmaceuticals Co., Ltd. appealed the ruling to a higher level court and the Company has not received the payment.  Considering the uncertainties of the legal proceeding, the Company did not record a contingent gain for this at September 30, 2007.  In December of 2005, the Company sued Hainan Haomai Pharmaceutical Co., Ltd. and Fuzhou Likang Pharmaceuticals Co., Ltd. for their infringement upon the patent of Etimicin transfusion. As the plaintiff, the Company has claimed compensation of approximately $38,590 for the infringement. According to the judges report from the local court in Haikou, PRC, on January 18, 2007, the Company won the lawsuit and Hainan Haomai Pharmaceutical Co., Ltd. and Fuzhou Likang Pharmaceuticals Co., Ltd. will pay $38,590 as compensation for the infringement.  However, Hainan Haomai Pharmaceutical Co., Ltd. and Fuzhou Likang Pharmaceuticals Co., Ltd. appealed the ruling to a higher level court and the Company has not received the payment.  Considering the uncertainties of the legal proceeding, the Company did not record a contingent gain for this at September 30, 2007.  In January 2007, the Company was sued by Jiangying Xinqiao Construction Co., Ltd for an overdue construction payment of $243,318. The local judge held a court in April, 2007 which was still in progress.  The Company believes the claim is without merit and plans to vigorously contend the claim. As such, there is no contingent accrual at September 30, 2007.


23


Item 2.  Managements Discussion and Analysis or Plan of Operation.  FORWARD-LOOKING STATEMENTS  We have included forward-looking statements in this report. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward looking statements. Without limiting the foregoing, words such as "may", "will", "expect", "believe", "anticipate", "estimate", "plan" or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors. Factors that might cause forward-looking statements to differ materially from actual results include, among other things, overall economic and business conditions, demand for the Company's products, competitive factors in the industries in which we compete or intend to compete, natural gas availability and cost and timing, impact and other uncertainties of our future acquisition plans.  GENERAL  Aida Pharmaceuticals Inc. (formerly known as BAS Consulting, Inc.) (the Company) was incorporated in the State of Nevada on December 18, 2002 (inception).  The Company attempted to operate as a consulting firm and was not successful.  The Company then began to seek an acquisition candidate and on December 8, 2005, we completed and closed the Share Exchange Agreement (the Agreement) dated as of June 1, 2005 by and among BAS Consulting, Inc., Earjoy Group Limited, a British Virgin Islands international business company (Earjoy), and the shareholders of Earjoy (the Earjoy Shareholders).  A copy of the Agreement was previously filed as an Exhibit to our Current Report on Form 8-K dated June 1, 2005 as filed with the Securities and Exchange Commission (the SEC) on June 15, 2005.  On March 6, 2006, the Company amended its Articles of Incorporation to change the name of the Company to Aida Pharmaceuticals, Inc. As a result of the acquisition, we now operate the business of AIDA Pharmaceuticals, Inc.  On July 5, 2006, the Company registered 2,500,000 shares of its common stock, $0.001 par value on Form S-8 with the Securities and Exchange Commission. Pursuant to the registration statement, the Company issued 2,000,000 shares to employees and consultants.  The Chinese pharmaceutical industry suffers from a relatively rigorous industrial environment since last year mainly due to the frequent strict regulation policies and personnel change from State Food and Drug Administration of the Peoples Republic of China (SFDA). This negatively affected the sales of the Company in a short term. The new medicine tender system for hospitals in some regions such as some east-south areas of China, in the beginning of 2007 requires the hospitals to purchase medicines and drugs only from the manufacturer of Pharmaceutical rather than distributors, which resulted in sales returns from some distributors.  OUR BUSINESS  AIDA Pharmaceuticals, Inc. has the following subsidiaries:  a) Earjoy Group Limited, (Earjoy) b) Hangzhou Aida Pharmaceutical Co., Ltd (Hangzhou Aida); c) Hangzhou Boda Medical Research and Development Co., Ltd. (Boda); d) Hainan Aike Pharmaceutical Co., Ltd. (Aike) and; e) Changzhou Fangyuan Pharmaceutical Co., Ltd. (Fangyuan) f) Shanghai Qiaer Bio-technology Co., Ltd (Qiaer)  Earjoy is an investment holding company.


24


Hangzhou Aida has been in operation since March 1999 and was established as a limited liability company under the laws of the Peoples Republic of China (PRC) on March 26, 1999.  On December 23, 2004, Earjoy entered into a Share Purchase Agreement with Best Nation Investment Co., Ltd. for the acquisition by Earjoy of 100% of all interests in Hangzhou Aida.  Hangzhou Aida is a fully integrated pharmaceutical company engaged in the development, manufacture, marketing, licensing, and distribution of pharmaceutical products primarily in Mainland China.  Aida (including its subsidiaries) has a total of nine production lines for the manufacturing of antibiotics, cardiovascular and anti-tumor drugs in various forms, including injectable powder, injectable liquid, capsules, tablets and ointments. All of them have been certified according to the Good Manufacturing Practices (GMP) guidelines issued by the State Food and Drug Administration of the People’s Republic of China (“SFDA”). Hangzhou Aida sells its Category-A antibiotic(Etimicin)under the trademark “Aida” and “PanNuo” etc. All these products are prescription drugs that are sold mainly to the hospitals in Mainland China.  Hangzhou Aidas strategy is to control all facets of its research and development efforts, including formulation development, clinical studies, regulatory submissions and manufacturing. In addition, the company markets its own branded products directly to health care professionals through its Mainland China sales operations. A key element of Hangzhou Aidas business is the development, manufacture and sale of branded pharmaceutical products that incorporate Hangzhou Aidas expertise in research and development and exclusive relationships with raw material suppliers, which provide significant therapeutic advantages over existing competing formulations.  Hangzhou Aida will also work to develop synergistic marketing partnerships in China and around the world in areas such as technology licensing, clinical research, product development, in-licensing and out-licensing of products, co-development and co-marketing agreements.  The headquarters of Hangzhou Aida is located in Hangzhou and Hangzhou Aida specializes in the production of Etimicin powder.  Boda is a wholly owned subsidiary of Hangzhou Aida and engages itself in the research and development of new drugs.  Aike was once a 50% owned subsidiary of Hangzhou Aida. In August 2006, Hangzhou Aida increased its position through an additional direct investment of $568,994 into Hainan Aike and making a $63,222 purchase of the interests held by a third-party institutional shareholder Merlin Green Canada Inc. Thereafter, Hainan Aike became a 60.61% owned subsidiary of the Company. Hangzhou Aida exercises significant influence over Aike by controlling over 60.61% of the voting rights and Aike owns 95% of Yangpu Aike Pharmaceutical Co., Ltd. (Yangpu). Aike specializes in the production of transfusion type of Etimicin AiYi.  Fangyuan is a 66% owned subsidiary of Hangzhou Aida. Fangyuan is sole supplier of the raw material of Etimicin and is also a major producer of the liquid type of Etimicin ChuangCheng.  The Company is capable of producing all types of Etimicin namely, powder, liquid and transfusion and thus has achieved a significant influence in the industry. This is a significant and unique advantage of the Company.  On August 8, 2006, the Company completed and closed the Share Purchase Agreements with Zhejiang Pharmaceutical Co., Ltd., Shanghai Handsome Biotech Co., Ltd and Zhongtuo Times Investment Co., Ltd. respectively. With these agreements, the Company acquired 77.5% of the outstanding shares of Shanghai Qiaer Bio-Technology Co., Ltd collectively.  Qiaer Bio-Tech was founded in 2001 and is located in the Zhangjiang Hi-tech development zone in Shanghai, China.  The key product of Qiaer Bio-Tech is rh-Apo21, a pioneering potential biopharmaceutical therapy with genetic engineering techniques used for cancers. Qiaer Bio-Tech has applied for three patents from the Chinese government authority, one of which has been granted with the other two in process. The Phase I clinical trial of rh-Apo2l has been successfully completed and the Phase II clinical trial has been initiated.


25


CRITICAL ACCOUNTING POLICIES AND ESTIMATES  We believe the following is among the most critical accounting policies that impact our consolidated financial statements. We suggest that our significant accounting policies, as described in our consolidated financial statements in the Summary of Significant Accounting Policies, be read in conjunction with this Management's Discussion and Analysis of Financial Condition and Results of Operations.  We recognize revenue in accordance with Staff Accounting Bulletin ("SAB") No. 104. All of the following criteria must exist in order for us to recognize revenue:  1. Persuasive evidence of an arrangement exists; 2. Delivery has occurred or services have been rendered; 3. The seller's price to the buyer is fixed or determinable; and 4. Collectibility is reasonably assured.  For fixed-priced refundable contracts, the Company recognizes revenue on a completion basis. Progress payments received/receivables are recognized as revenue only if the specified criteria is achieved, accepted by the customer, confirmed not refundable and continued performance of future research and development services related to the criteria are not required.  We have identified one policy area as critical to the understanding of our consolidated financial statements. The preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of sales and expenses during the reporting periods. With respect to net realizable value of the Company's accounts receivable, Long-lived assets and inventories, significant estimation judgments are made and actual results could differ materially from these estimates.  For the three and nine months ended September 30, 2007, management of the Company provided a reserve on its accounts receivable to reflect managements expectation on the collectibility of aged accounts receivable. Managements estimation of the reserve on accounts receivable at September 30, 2007 was based on the current facts that there are aged accounts receivable. Management has assessed the customers ability to continue to pay the outstanding invoices timely, and whether their financial position will deteriorate significantly in the future which would result in their inability to pay their debts to the Company.  For the three and nine months ended September 30, 2007, the Company had made no impairments for Long-lived assets. Long-lived assets of the Company are reviewed annually as to whether their carrying value has become impaired, pursuant to the guidelines established in SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets". The Company also periodically evaluates the amortization periods of its depreciable assets to determine whether subsequent events and circumstances warrant revised estimates of the useful lives.  Management's estimation whether a provision is needed is based on managements analysis of the current facts of whether potential impairments on the current carrying value of the inventories due to potential obsolescence exist as a result of aged inventories. In making their judgments, management made their estimations of the potential impairments based on the demand for their products in the future and the trends of turnover of the inventories.  While the Company's management currently believes that there is little likelihood that the actual results of their current estimates will differ materially from such current estimates, if the financial position of its customers deteriorates, if there is a significant reduction in the carrying value of its Long-lived assets, or if, customer demand for its products decreases significantly in the near future, the Company could realize significant write downs for uncollectible accounts receivable, impairment of Long-lived assets or slow moving inventories.


26


Effective January 1, 2007, the Company adopted Financial Accounting Standards Board (FASB) Interpretation No. 48, Accounting for Uncertainty in Income Taxes ("FIN 48"), an interpretation of FASB statement No. 109, Accounting for Income Taxes. The interpretation addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under FIN 48, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. FIN 48 also provides guidance on derecognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of June 30, 2007, the Company does not have a liability for unrecognized tax benefits.  In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements," which provides enhanced guidance for using fair value to measure assets and liabilities. SFAS No. 157 provides a common definition of fair value and establishes a framework to make the measurement of fair value in generally accepted accounting principles more consistent and comparable. SFAS No. 157 also requires expanded disclosures to provide information about the extent to which fair value is used to measure assets and liabilities, the methods and assumptions used to measure fair value, and the effect of fair value measures on earnings. SFAS No. 157 is effective for financial statements issued in fiscal years beginning after November 15, 2007 and to interim periods within those fiscal years. The Company is currently in the process of evaluating the effect, if any, the adoption of SFAS No. 157 will have on its consolidated results of operations, financial position, or cash flows.  In February 2007, the FASB issued FASB Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities −− Including an amendment of FASB Statement No. 115 (“FAS 159”). FAS 159, which becomes effective for the Company on January 1, 2008. This standard permits companies to choose to measure many financial instruments and certain other items at fair value and report unrealized gains and losses in earnings. Such accounting is optional and is generally to be applied instrument by instrument. The Company does not anticipate that election, if any, of this fair-value option will have a material effect on the results or operations or consolidated financial position  RESULTS OF OPERATIONS  THREE MONTHS ENDED SEPTEMBER 30, 2007 AS COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2006  The following table sets forth selected statements of income data as a percentage of revenues for the three months indicated.  Three Months Ended September 30,20072006Revenues, net100.00%100.00%Cost of goods sold(48.25)%(44.19)%Gross margin51.75%55.81%Selling and distribution(18.82)%(16.73)%General and administrative(13.44)%(18.60)%Research and development(1.01)%(0.65)%Other expense(5.87)%0.21%Income taxes(2.08)%(3.10)%Minority interests(3.49)%(3.86)%Net (loss) income7.04%13.09%


27


Revenues, Cost of Goods Sold and Gross Profit Revenues for the three months ended September 30, 2007 were $7,373,770 an increase of $349,879 from $7,023,891 for the three months ended September 30, 2006. Compared to the third quarter of 2006, the increase in sales revenues from our group of companies engaging in the production of different types of Etimicin for the third quarter of 2007 and 2006 were as follows:  Three Months Ended September 30,Companies20072006Increase/
(Decrease)Hangzhou Aida Pharmaceutical
Co., Ltd (Hangzhou Aida) specializes
in the production of Etimicin
powder$2,524,765$2,759,390$(234,625)Hainan Aike pharmaceutical
Co., Ltd (Aike) specializes
in the production of Etimicin
transfusion3,069,3792,838,064231,315Changzhou Fangyuan Pharmaceutical  Co.,
Ltd. (Fangyuan) specializes
in the production of Etimicin
injection1,779,6261,426,437353,189TOTAL$7,373,770$7,023,891$349,879  For the three months ended September 30, 2007, the sales of Hangzhou Aida decreased by $234,625 or 8.50% as compared to the same period of 2006. The decrease in sales is mainly attributable to the decrease in sales of the Etimicin powder, Aida.  For the three months ended September 30, 2007, the sales of Hainan Aike increased by $231,315 or 8.15% as compared to the same period of 2006. The increase in sales can mainly be accounted for the increase in sales of the Etimicin transfusion product, Aiyi.  For the three months ended September 30, 2007, the sales of Fangyuan increased by $353,189 or 24.76% as compared to the same period of 2006. The increase in sales is mainly attributable to an increase in sales of Etimicin material product.  The cost of goods sold for the third quarter ended June 30, 2007 was $3,557,685 an increase of $454,169 from $3,103,516 for the same period of 2006. The increase in cost of goods sold can be analyzed as follows:


28


Three Months Ended September 30,Companies20072006Increase/
(Decrease)Hangzhou Aida Pharmaceutical Co. Ltd (Hangzhou Aida) specializes in the production of Etimicin powder$846,239$940,872$(94,633)Hainan Aike pharmaceuticalCo. Ltd (Aike) specializesin the production of Etimicin
transfusion1,941,0991,724,307216,792Changzhou Fangyuan Pharmaceutical
Ltd. (Fangyuan) specializesin the production of Etimicininjection770,347438,337332,010TOTAL$3,557,685$3,103,516$454,169  The cost of goods sold of Hangzhou Aida for the three months ended September 30, 2007 decreased by $94,633, or 10.06% compared to $940,872 for the same period in 2006. The decrease in the cost of goods sold can mainly be accounted for by a decrease in sales.  The cost of goods sold of Aike for the three months ended September 30, 2007 increased by $216,792, or 12.57% compared to $1,724,307for the same period in 2006. The increase can mainly be explained by the decrease in sales.  The cost of goods sold of Fangyuan for the three months ended September 30, 2007 increased by $332,010, or 75.74% compared to $438,337 for the same period in 2006.The increase is mainly due to the increase in sales.  Compared to the three months ended September 30, 2006, the percentage gross profit margin for our Company decreased from 55.81% to 51.75% for the third quarter ended June 30, 2007.  Research and Developments The cost of the research and development for the third quarter of 2007 was 74,514 representing the cost incurred for the clinical trials for Rh-Apo2l by Qiaer, as compared to $45,323 for the third quarter of 2006.   Selling and Distribution Selling and distribution expenses increased from $1,175,000 for the three months ended September 30, 2006 to $1,387,818 for the same period this year, or a 18.11% increase.Compared to the same period in 2006, our increase in the expenses was because of the following:


29


Three Months Ended September 30,Breakdown of Expenses20072006Increase/
(Decrease)Traveling expenses$422,580$523,221$(100,641)Office expenses202,815210,595(7,780)Payroll131,08752,41878,669Conference fees76,86917,27559,594Rent83,90612,77471,132Entertainment157,45242,368115,084Advertising expenses17,190162,653(145,463)Other expenses295,919153,696142,223TOTAL$1,387,818$1,175,000$212,818  For the three months ended September 30, 2007 traveling expenses and office expenses decreased by $100,641 and 7,780, respectively, compared with the same period last year. The decrease was mainly explained that the Company controlled the traveling and office expenses by effective administration.  For the three months ended September 30, 2007 advertising expenses decreased by $145,463, compared with the same period last year. The decrease was mainly explained that the Company carried out several great advertisements for sales promotion in the third quarter last year and no such great advertisements for the same period this year.  For the three months ended September 30, 2007, the rent expenses of $83,906 incurred for Aike, increased by $71,132, compared to $12,774 for the same period last year.  General and Administrative General and administrative expenses decreased from $1,306,226 for the three months ended September 30, 2006 to $991,216 for the same period this year, representing a 24.12% decrease. The details of general and administrative expenses for the three months ended September 30, 2007 and 2006 were as follows:  Three Months Ended September 30,Breakdown of Expenses20072006Increase/
(Decrease)Traveling expenses$27,679$49,643$(21,964)Office expenses58,94546,02112,924Payroll97,654140,111(42,457)Conference fees19,32217,8001,522Labor union & education & staff welfare132,601140,097(7,496)Consultancy fees70,782138,357(67,575)Entertainment37,81024,71613,094Depreciation119,68182,09237,589Amortization of intangible assets163,064452,463(289,399)Other expenses263,678214,92648,752TOTAL$991,216$1,306,226$(315,010)


30


The consultancy fees which the company pays consultants for their consultation service decreased from $138,357 for the three months ended September 30, 2006 to $70,782 for the same period this year. The decrease was mainly attributable to a decrease of $79,360 in consultation service of Aida in the third quarter this year.  Amortization of intangible assets of $163,064 for the three months ended September 30, 2007 decreased by $289,399 from $452,463 for the same period last year. The decrease was explained by that amortization of deferred expense of $311,044 for the third quarter of 2006. On July 5, 2006, the Company issued 800,000 and 1,200,000 shares of common stock on Form S-8 with the Securities and Exchange Commission to employees and consultants, respectively. The deferred compensation is amortized over the service period.  Depreciation expenses of $119,681 for the three months ended September 30, 2007 increased by $37,589 from $82,092 fot the same period last year. The increase was mainly attributable to an increase of $28,431 in the depreciation expenses for Aida.  Other Income (Expenses) Other income (expenses) decreased from $14,551 for the three months ended September 30, 2006 to $(433,086) for the same period this year. The other income (expenses) for the three months Ended September 30, 2007 and 2006 were as follows:  Three Months Ended September 30,Breakdown of Other Income (Expenses)20072006Increase/
(Decrease)Interest expense, net$(465,282)$(459,511)$(5,771)Government grants46,131551,420(505,289)Investment income (loss)(10,457)-(10,457)Other (loss) income, net(3,478)(77,358)73,880TOTAL$(433,086)$14,551$(447,637)  Net Interest expense for the three months ended September 30, 2007 increased slightly by $5,771 from $459,511 for the same period last year.  Government grants of $551,420 for the three months ended September 30, 2006 represented subsidies from the government. such income of $46,131 occurred for the same period this year.  Investment income (loss) of $(10,457) for the three months ended September 30, 2007 was mainly explained that he Company entered into agreement with Hangzhou Handcrafts Cooperate Association to transfer its 10.6% interest in Hangzhou Longde Medicine Machinery Co., Ltd. for $93,199 resulting in a loss of $14,285.And no such income occurred for the same period of 2006.  Income Taxes Income tax expense was $153,182 for the three months ended September 30, 2007, as compared to $217,720 for the same period last year.  In accordance with the relevant tax laws and regulations of PRC, the corporation income tax rate is 33%. As a Company registered in Hainan, PRC, Aike is entitled a beneficial corporate income tax rate of 15% in accordance with the relevant tax laws in the PRC. Fangyuan enjoys a beneficial tax rate of 15% as it is registered in a national high-tech development zone. According to the relevant laws and regulations of PRC, the preferential tax rate of 15% is applied to companies established in the national high-tech development zone.


31


In accordance with the relevant taxation laws in the PRC, from the time that a company has its first profitable tax year, a foreign investment company is exempt from corporate income tax for its first two years and is then entitled to a 50% tax reduction for the succeeding three years. And the foreign investment company income tax rate is 27% in Hangzhou, PRC. Since Hangzhou Aida Pharmaceutical Co., Ltd has been a foreign investment company since 2004, so we are entitled to a 50% tax reduction in 2007.  Net (Loss) Income In the third quarter of 2007, our net income decreased by $400,224 to a net income of $519,061 from $919,285 in the same period in 2006.  RESULTS OF OPERATIONS  NINE MONTHS ENDED SEPTEMBER 30, 2007 AS COMPARED TO SIX MONTHS ENDED SEPTEMBER 30, 2006  The following table sets forth selected statements of income data as a percentage of revenues for the nine months indicated.  Nine Months Ended September 30,20072006Revenues, net100.00%100.00%Cost of goods sold(52.13)%(49.24)%Gross margin47.87%50.76%Selling and distribution(18.81)%(24.05)%General and administrative(16.09)%(14.73)%Research and development(1.27)%(0.23)%Other income (expense)(5.87)%(0.64)%Income taxes(1.02)%(2.26)%Minority interests(3.01)%(2.10)%Net (loss) income1.78%6.75%  Revenues, Cost of Goods Sold and Gross Profit Revenues for the nine months ended September 30, 2007 were $18,687,283 a decrease of $971,952 from $19,659,235 for the same time last year. Compared to the nine months of 2006, the decrease in sales revenues from our group of companies engaging in the production of different types of Etimicin for the nine months of 2007 and 2006 were as follows:


32


Nine Months Ended September 30,Companies20072006Increase/
(Decrease)Hangzhou Aida Pharmaceutical Co., Ltd (Hangzhou Aida) specializes in the production of Etimicin powder$5,347,266$6,830,259$(1,482,993)Hainan Aike pharmaceutical Co., Ltd (Aike) specializes in the production of Etimicin transfusion9,087,9669,609,484(521,518)Changzhou Fangyuan Pharmaceutical  Co., Ltd. (Fangyuan) specializes in the production of Etimicin injection4,252,0513,219,4921,032,559TOTAL$18,687,283$19,659,235$(971,952)  For the nine months ended September 30, 2007, the sales of Hangzhou Aida decreased by $1,482,993 or 21.71% as compared to the same period of 2006. The Chinese pharmaceutical industry suffers from a relatively rigorous industrial environment since last year mainly due to the frequent strict regulation policies and personnel change from SFDA. This negatively affected the sales of the Company in the short term. The new medicine tender system for hospitals in some regions such as some east-south areas of China, in the beginning of 2007 requires the hospitals to purchase medicines and drugs only from the manufacturer of Pharmaceutical rather than distributors, which resulted in sales returns from some distributors. The Company believes after renewal of distribution channel and rapid adaptation to the new system, we can overcome the short period disadvantage. In a view of the long run, the Company will benefit a lot from the restructuring of the industry and government regulation as a well-disciplined and innovative company. Meanwhile, some other Etimicin manufacturers who infringed the patent of Etimicin also created disorder of the market, thus bringing negative impact against the business performance of the company. But with the successful ongoing of the legal action, we believe that those manufacturers will stop producing and selling shortly. We see the recovery of our sales from the second quarter compared with that in the first quarter of this year. We believe that our operation and growth will continue to recover in the coming quarters. We also expect that the commercialization of our new drugs will improve the heavy reliance on Etimicin and lessen the fluctuation of our performance.  For the nine months ended September 30, 2007, the sales of Hainan Aike decreased by $521,518 or 5.43% as compared to the same period of 2006. The decrease in sales can mainly be accounted for the slight decrease in sales of the Etimicin transfusion product, Aiyi.  For the nine months ended September 30, 2007, the sales of Fangyuan increased by $1,032,559 or 32.07% as compared to the same period of 2006. The increase in sales is the result of the intense marketing and promotion programs of a new Etimicin injection product, Chuangcheng. Another reason is the increase in sales of the Etimicin material product.


33


The cost of goods sold for the nine months ended September 30, 2007 was $9,740,952 an increase of $61,385 from $9,679,567, for the year 2006. The increase in cost of goods sold can be analyzed as follows:  Nine Months Ended September 30,Companies20072006Increase/
(Decrease)Hangzhou Aida Pharmaceutical Co. Ltd (Hangzhou Aida) specializes in the production of Etimicin powder$1,677,909$1,959,058$(281,149)Hainan Aike pharmaceuticalCo. Ltd (Aike) specializesin the production of Etimicin
transfusion5,591,9755,955,803(363,828)Changzhou Fangyuan Pharmaceutical
Ltd. (Fangyuan) specializesin the production of Etimicininjection2,471,0681,764,706706,362TOTAL$9,740,952$9,679,567$61,385  The cost of goods sold of Hangzhou Aida for the nine months ended September 30, 2007 decreased by $281,149, or 14.35% compared to $1,959,058 for the same period in 2006. The decrease in the cost of goods sold can mainly be accounted for by a decrease in sales by 21.71%.  The cost of goods sold of Aike for the nine months ended September 30, 2007 decreased by $363,828, or 6.11% compared to $5,5955,803 for the same period in 2006. The increase can mainly be explained by the decrease in sales.  The cost of goods sold of Fangyuan for the nine months ended September 30, 2007 increased by $706,362, compared to $1,764,706 for the same period in 2006.The increase is mainly due to the increase in sales.  Compared to the nine months ended September 30, 2006, the percentage gross profit margin for our Company decreased from 50.76% to 47.87% for the same period in 2007.  Research and Developments The cost of the research and development for the nine months ended September 30, 2007 was 238,159 representing the cost incurred for the clinical trials for Rh-Apo2l by Qiaer, as compared to $45,111 for the same period of 2006.  Selling and Distribution Selling and distribution expenses decreased from $4,728,989 for the nine months ended September 30, 2006 to $3,515,776 for the same period this year, or a 25.65% decrease.Compared to the same period in 2006, our decrease in the expenses was because of the following:


34


Nine Months Ended September 30,Breakdown of Expenses20072006Increase/
(Decrease)Traveling expenses$1,081,5451,713,380$(631,835)Sale commissions81,084431,207(350,123)Office expenses632,859799,684(166,825)Payroll343,879249,09894,781Conference fees136,786141,647(4,861)Rent283,638105,807177,831Entertainment351,711117,031234,680Advertising expenses21,873566,413(544,540)Other expenses582,401604,722(22,321)TOTAL$3,515,776$4,728,989$(1,213,213)  For the nine months ended September 30, 2007 sale commissions of $81,084 decreased by $350,123, compared with the same period last year. The decrease was due to the decrease in the sales with commissions for Fangyuan.  For the nine months ended September 30, 2007 traveling expenses, office expenses and advertising expenses decreased by $631,835, $166,825 and $544,540 respectively, compared with the same period last year. The decrease was mainly explained that the Company controlled the selling expenses by effective administration.  For the nine months ended September 30, 2007, the rent expenses of $283,638 incurred for the Beijing office , the biggest sales office for Aike, increased by $177,831, compared to $105,807 for the same period last year.  General and Administrative General and administrative expenses increased from $2,896,205 for the nine months ended September 30, 2006 to $3,006,799 for the same period this year, representing a 3.82% increase. The details of general and administrative expenses For the nine months ended September 30, 2007 and 2006 were as follows:  Nine Months Ended September 30,Breakdown of Expenses20072006Increase/
(Decrease)Traveling expenses$203,104$188,765$14,339Office expenses157,273133,07324,200Payroll526,580422,687103,893Conference fees42,25327,56414,689Labor union & education & staff welfare590,563417,895172,668Consultancy fees160,150245,646(85,496)Entertainment173,15875,77097,388Depreciation328,248230,21298,036Amortization of intangible assets537,449680,617(143,168)Other expenses288,021473,976(185,955)TOTAL$3,006,799$2,896,205$110,594  The labor union expenses & education expenses & staff welfare of $590,563 for the nine months ended September 30, 2007 increased by $172,668 from $417,895 for the same period last year. The increase was explained by the increase in the payroll per staff. And the payroll expenses of $526,580 for the nine months ended September 30, 2007 increased by $103,893 from $422,687 for the same period last year.


35


Amortization of intangible assets of $537,449 for the nine months ended September 30, 2007 decreased by $143,168 from $680,617 for the same period last year. The decrease was explained by that amortization of deferred expense of $311,044 for the third quarter of 2006. On July 5, 2006, the Company issued 800,000 and 1,200,000 shares of common stock on Form S-8 with the Securities and Exchange Commission to employees and consultants, respectively. The deferred compensation is amortized over the service period.  Depreciation expenses of $328,248 for the nine months ended September 30, 2007 increased by $98,036 from $230,212 for the same period last year. The increase was mainly attributable to an increase of $42,302 in the depreciation expenses for Fangyuan.  Other Income (Expenses) Other income (expenses) decreased from $(124,625) for the nine months ended September 30, 2006 to $(1,097,792) for the same period this year. The other income (expenses) for the nine months ended September 30, 2007 and 2006 were as follows:  Nine Months Ended September 30,Breakdown of other income/(expenses)20072006Increase/
(Decrease)Interest expense, net$(1,180,813)$(1,114,105)$(66,708)Government grants95,9981,097,724(1,001,726)Investment income(10,457)12,490(22,947)Gain on sale of marketable securities120,356-120,356Other (loss) income, net(122,876)(120,734)(2,142)TOTAL$(1,097,792)$(124,625)$(973,167)  Net Interest expense for the nine months ended September 30, 2007 increased by $66,708 from $1,114,105 for the same period last year. The increase is mainly due to an increase in the interest for the short-term borrowings.  Government grants for the nine months ended September 30, 2007 decreased by $1,001,726 from $1,097,724 for the same period last year. The decrease is due to the decrease in subsidies from the government.  Investment income of $12,490 for the nine months ended  September 30, 2006 represented the sold income of 8.33% outstanding shares of Zhejiang Anglikang Pharmaceutical Co., Ltd at a price of $12,490 and the investment income (loss) of $(10,457) for the same period this year was mainly explained that he Company entered into agreement with Hangzhou Handcrafts Cooperate Association to transfer its 10.6% interest in Hangzhou Longde Medicine Machinery Co., Ltd. for $93,199 resulting in a loss of $14,285  Gain on sale of marketable securities of $120,356 for the nine months ended September 30, 2007 represented income from Chinese securities investment and no such income was incurred for the same period last year.  Income Taxes Income tax expense was $191,349 for the nine months ended September 30, 2007, as compared to $445,047for the same period last year.  In accordance with the relevant tax laws and regulations of PRC, the corporation income tax rate is 33%. As a Company registered in Hainan, PRC, Aike is entitled a beneficial corporate income tax rate of 15% in accordance with the relevant tax laws in the PRC. Fangyuan enjoys a beneficial tax rate of 15% as it is registered in a national high-tech development zone. According to the relevant laws and regulations of PRC, the preferential tax rate of 15% is applied to companies established in the national high-tech development zone.


36


In accordance with the relevant taxation laws in the PRC, from the time that a company has its first profitable tax year, a foreign investment company  is exempt from corporate income tax for its first two years and is then entitled to a 50% tax reduction for the succeeding three years. And the foreign investment company income tax rate is 27% in Hangzhou, PRC. Since Hangzhou Aida Pharmaceutical Co., Ltd has been a foreign investment company since 2004, so we are entitled to a 50% tax reduction in 2007.  Net (loss) Income For the nine months ended September 30, 2007, our net income decreased by $993,285 to a net income of $333,388 from $1,326,673 in the same period in 2006.  LIQUIDITY AND CAPITAL RESOURCES  Cash Our cash balance increased by $1,576,484 to $7,693,300 as of September 30, 2007, as compared to $6,116,816 as of December 31, 2006. The increase was mainly attributable to cash in flow of financing activities and depreciation and amortization of $3,058,496 and $1,476,339, respectively, a decrease in accounts receivable of $5,566,175. The increase in cash flow was partially offset by cash out flow of investment activities of $7,940,071, an increase in inventories of $1,319,475, and a decrease in accounts payable of $885,626. The net cash flow was $1,576,484 for the nine months ended September 30, 2007.  Our cash flow from operations amounted to $6,506,533 for the nine months ended September 30, 2007, compared to $579,266 for the same period last year.  Our cash flow used in investing activities amounted to $7,940,071 of which $2,312,740 was issuance of notes receivable. The Company invested $2,578,149 in the deposit for long term investment, invested $1,924,724 in the purchases of plant and equipment and lent to employees $1,279,916.  The net cash used in financing activities amounted to $3,058,496 of which $23,290,420 was the proceeds from short-term debt.  At September 30, 2007, the Company had short-term debt of $29,405,234 of which $22,507,589 was short-term bank borrowings and the remaining $6,897,645 represented notes payable to unrelated parties. The interest for the short-term borrowings varied from 5.3625% to 8.541% per annum whereas the notes payable to unrelated parties is interest free. The Company believes that the cash generated from normal operation will be sufficient to pay off its liabilities as the short-term borrowings and commitments fall due.  Working Capital Our working capital deficiency increased by $3,099,206to $8,848,137 at September 30, 2007, as compared to $5,748,931 at December 31, 2006. The increase in working capital deficiency at September 30, 2007 was mainly attributable to our increase in short term debt of $5,489,782 and customer deposits of $727,669 and a decrease in accounts receivable of $5,582,631 offset by the decrease in accounts payable and current portion of long-term debt of $885,627 and $2,385,964 and an increase in cash of $1,576,484, notes receivable of $1,403,648, due from employees of $1,279,915 and inventories of $1,319,475.  The Company currently generates its cash flow through operations and the Company believes that its cash flow generated from operations will be sufficient to sustain operations for the next twelve months. Also, from time to time, the Company may require extra funding through financing activities and investments for expansion. Also, from time to time, the Company may come up with new expansion opportunities for which our management may consider seeking external funding and financing. However, as of September 30, 2007, the Company had no solid plan for additional capital through external funding and financing.


37


Item 3.  Controls and Procedures.  (a) Evaluation of Disclosure Controls and Procedures.  Within the 90 days prior to the date of this Quarterly Report for the period ended September 30, 2006, we carried out an evaluation, under the supervision and with the participation of our management, including the Company's Chairman and Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-14 of the Securities Exchange Act of 1934 (the "Exchange Act"), which disclosure controls and procedures are designed to insure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized and reported within required time periods specified by the SEC's rules and forms. Based upon that evaluation, the Chairman and the Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to the Company required to be included in the Company's period SEC filings.  (b) Changes in Internal Controls.  Subsequent to the date of such evaluation as described in subparagraph (a) above, there were no significant changes in our internal controls or other factors that could significantly affect these controls, including any corrective action with regard to significant deficiencies and material weaknesses.  PART II  OTHER INFORMATION  Item 1. Legal Proceedings.  In 2006, the Company brought a legal action against Jiangxi Pharmaceutical Co., Ltd. and Hainan Licheng Pharmaceuticals Co., Ltd. for their infringement upon the patent of Etimicin transfusion. As the plaintiff, the Company has claimed compensation of approximately $38,590 for the infringement. According to the judges report from the local court in Haikou, PRC, on December 30, 2006, the Company won the lawsuit and Hainan Haomai Pharmaceutical Co. Ltd. and Fuzhou Likang Pharmaceuticals Co., Ltd. will be required to pay $38,590 as compensation to the Company. However, Jiangxi Pharmaceutical Co., Ltd. and Hainan Licheng Pharmaceuticals Co., Ltd. appealed the ruling to a higher level court and the Company has not received the payment.  In December of 2005, the Company sued Hainan Haomai Pharmaceutical Co., Ltd. and Fuzhou Likang Pharmaceuticals Co., Ltd. for their infringement upon the patent of Etimicin transfusion. As the plaintiff, the Company has claimed compensation of approximately $38,590 for the infringement. According to the judges report from the local court in Haikou, PRC, on January 18, 2007, the Company won the lawsuit and Hainan Haomai Pharmaceutical Co., Ltd. and Fuzhou Likang Pharmaceuticals Co., Ltd. will pay $38,590 as compensation for the infringement.  However, Hainan Haomai Pharmaceutical Co., Ltd. and Fuzhou Likang Pharmaceuticals Co., Ltd. appealed the ruling to a higher level court and the Company has not received the payment.  In January 2007, the Company was sued by Jiangying Xinqiao Construction Co., Ltd for an overdue construction payment of $243,318. The Company believes the claim is without merit and plans to vigorously contend the claim. As such, there is no contingent accrual at September 30, 2007.  Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds  None.  Item 3.  Defaults Upon Senior Securities  None.


38


Item 4.  Submission of Matters to a Vote of Security Holders.  None.  Item 5.  Other Information  Not applicable.  Item 6.  Exhibits  Exhibits  Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-B.  Exhibit No. SEC Ref. No. Title of Document  1 31.1 Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  2. 31.2 Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  3 32.1 Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*  4 32.2 Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*  *The Exhibit attached to this Form 10-QSB shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.


39


SIGNATURES  In accordance with the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.   AIDA PHARMACEUTICALS, INC.    Date: November 14, 2007 /s/ Biao Jin Mr. Biao Jin Chief Executive Officer     Date: November 14, 2007 /s/ Hui Lin Ms. Hui Lin Chief Financial Officer


40